세계의 외상성 뇌손상 치료학 시장

Global Traumatic Brain Injury Therapeutics Market to Reach US$13.7 Billion by 2030

The global market for Traumatic Brain Injury Therapeutics estimated at US$5.9 Billion in the year 2023, is expected to reach US$13.7 Billion by 2030, growing at a CAGR of 12.7% over the analysis period 2023-2030. Acetylcholinesterase Inhibitors, one of the segments analyzed in the report, is expected to record a 12.5% CAGR and reach US$3.8 Billion by the end of the analysis period. Growth in the Erythropoietin Drugs segment is estimated at 11.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 11.8% CAGR

The Traumatic Brain Injury Therapeutics market in the U.S. is estimated at US$1.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 11.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.6% and 10.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.3% CAGR.

Global Traumatic Brain Injury Therapeutics Market - Key Trends and Drivers Summarized

Traumatic brain injury (TBI) is a significant public health concern, affecting millions of people worldwide each year. TBI occurs when an external force injures the brain, which can result from falls, motor vehicle accidents, sports injuries, or assaults. The severity of TBI ranges from mild concussions to severe brain damage, leading to long-term disabilities or even death. Current therapeutic strategies for TBI include acute interventions, such as surgery to reduce intracranial pressure and prevent further injury, as well as long-term rehabilitation efforts to address cognitive, physical, and emotional impairments. Pharmacological treatments are aimed at managing symptoms and preventing secondary brain damage caused by inflammation, oxidative stress, and excitotoxicity. Despite the array of interventions, effective treatments that can significantly alter the course of TBI remain limited, highlighting a critical need for innovative therapeutic approaches.

Recent advancements in the understanding of TBI pathophysiology have paved the way for novel therapeutic strategies. Research into neuroprotective agents, such as antioxidants, anti-inflammatory drugs, and calcium channel blockers, shows promise in mitigating the secondary damage following the initial injury. Stem cell therapy is another emerging field, offering potential for tissue regeneration and functional recovery. Additionally, advancements in biomarker discovery are enhancing the ability to diagnose TBI accurately and monitor treatment efficacy, paving the way for more personalized treatment plans. Non-pharmacological interventions, including hyperbaric oxygen therapy and transcranial magnetic stimulation, are also being explored for their potential to enhance neuroplasticity and recovery. These innovative approaches are driven by a deeper understanding of the complex mechanisms underlying TBI, aiming to provide more effective and comprehensive care for patients.

The growth in the TBI therapeutics market is driven by several factors. The increasing incidence of TBI due to sports activities, military conflicts, and road accidents has heightened the demand for effective treatments. Technological advancements in diagnostic tools, such as advanced imaging techniques and biomarker assays, have improved the accuracy of TBI diagnosis and the monitoring of treatment progress. The expanding field of regenerative medicine, particularly stem cell research, offers new avenues for therapeutic interventions that were previously unattainable. Moreover, the growing awareness of the long-term impact of TBI on quality of life is propelling investment in research and development of new treatments. Government initiatives and funding aimed at improving outcomes for TBI patients, along with collaborations between academic institutions and pharmaceutical companies, are also fostering innovation in this field. Additionally, the rise of personalized medicine is driving the development of tailored therapeutic approaches that address the unique needs of each patient, enhancing the overall efficacy of TBI treatments. Collectively, these factors are contributing to a dynamic and rapidly evolving market for traumatic brain injury therapeutics.

Select Competitors (Total 86 Featured) -

• Abliva
• Algernon Pharmaceuticals Inc.
• Altasciences
• Astrocyte Pharmaceuticals Inc.
• Beyond Barriers Therapeutics, Inc.
• Cellvation, Inc.
• Ischemix
• Mitochon Pharmaceuticals
• NervGen Pharma Corp.
• Neuren Pharmaceuticals Ltd.
• SanBio Company Limited
• Symbinas Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.
• ZyVersa Therapeutics, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Traumatic Brain Injury Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of TBI Spurs Demand for Effective Therapies
  • Advances in Diagnostic Tools Propel Growth in Market Adoption
  • Technological Innovations in Imaging Techniques Expand Addressable Market Opportunity
  • Emergence of Neuroprotective Agents Strengthens Business Case for Novel Treatments
  • Development of Stem Cell Therapies Generates New Market Opportunities
  • Growing Focus on Personalized Medicine Drives Adoption of Tailored Therapeutic Approaches
  • Enhanced Understanding of TBI Pathophysiology Drives Market Dynamics
  • Growing Awareness of Long-Term Impact of TBI Throws the Spotlight On Need for Comprehensive Care
  • Expanding Field of Regenerative Medicine Sustains Growth in Therapeutic Interventions
  • Integration of Biomarker Discovery and Use in Diagnostics and Treatment Monitoring Generates Demand
  • Non-Pharmacological Interventions, Such as Hyperbaric Oxygen Therapy, Propel Market Growth
  • Increasing Number of Sports-Related TBIs Drives Market Demand
  • Advancements in Transcranial Magnetic Stimulation Generate New Treatment Opportunities
  • Here's the Story: Impact of Military Conflicts on TBI Incidence and Therapeutic Needs
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Traumatic Brain Injury Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Traumatic Brain Injury Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Traumatic Brain Injury Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Acetylcholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Acetylcholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Acetylcholinesterase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Erythropoietin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Erythropoietin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Erythropoietin Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Growth Hormone Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Growth Hormone Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Growth Hormone Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Stem Cells Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Stem Cells Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Stem Cells Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 20: USA Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 21: USA Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: USA 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 23: Canada Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 24: Canada Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: Canada 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• JAPAN
  • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 26: Japan Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Japan Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: Japan 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• CHINA
  • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 29: China Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: China Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: China 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• EUROPE
  • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 32: Europe Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 33: Europe Historic Review for Traumatic Brain Injury Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: Europe 16-Year Perspective for Traumatic Brain Injury Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 35: Europe Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Europe Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Europe 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• FRANCE
  • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 38: France Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: France Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: France 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• GERMANY
  • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 41: Germany Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Germany Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Germany 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 44: Italy Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Italy Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Italy 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 47: UK Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: UK Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: UK 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Rest of Europe Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Rest of Europe 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Asia-Pacific Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Asia-Pacific 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 56: Rest of World Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Rest of World Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Rest of World 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030

IV. COMPETITION